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Carotid Body-Mediated 
  , Camilo L , 
per se
Heart failure (HF) is a global public health problem. Currently, it is estimated that 26 million people worldwide are 
living with this condition, a!ecting approximately 20% of the world population over 75 years of age, and resulting 
in more than 1 million hospitalizations annually in both the United States and Europe1, 2. HF is a disease with very 
poor prognosis despite advances in treatment; half of the patients with HF are likely to die in a 4 year time-frame 
once diagnosed, while more than 50% with severe cardiac dysfunction are likely to die within one year3. 
Development of HF is driven by a complex interaction of multiple pathophysiological stimuli; however chronic 
hyper-activation of the sympathetic nervous system is widely considered to be a major contributor to disease 
progression4. Importantly, several studies suggest that an enhanced carotid body (CB) chemore"ex contributes to 
sympathetic activation in HF patients5 and experimental models of HF6. However, the mechanisms responsible 
for enhanced CB activity in HF are not fully understood.
#e CB is the main peripheral arterial chemoreceptor7, 8 mediating a re"ex response during acute and chronic 
alterations in the arterial levels of pO2, pCO2, pH, glucose, temperature and blood "ow
9–11. In HF patients as 
well as in animal models, CB function is potentiated during HF leading to sympathoexcitation which in turn 
further stresses the failing heart. #e pivotal contribution of the CB to the progression of HF pathophysiology 
was shown in recent studies in which CB denervation during the progression of HF in rabbits and rats resulted in 
normalized autonomic control12 and marked improvement in survival13. Previous work indicates that decreased 
antioxidant enzyme expression14, 15, increased pro-oxidant enzyme expression16, and increased CB angiotensin II 
levels and angiotensin II type 1 receptor expression17 contribute to enhanced CB chemore"ex function in HF. #e 
main pathophysiological signal that triggers these biochemical changes in the CB remains to be elucidated. Ding 
and colleagues (2011) showed for the $rst time that control rabbits subjected to chronic carotid artery occlusion 
using pneumatic cu! occluders resulted in chemore"ex activation and autonomic imbalance that was similar 
to that observed in HF animals11. In addition, Krüppel like factor 2 (KLF2), a mechanosensitive transcription 
factor that mediates the endothelium response to changes in blood "ow and shear stress18, has been described 
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to be constitutively expressed in the CB19, 20. Haack, et al.20 showed that in myocardial infarcted HF rats, CB 
KLF2 expression was signi$cantly lower than in sham animals20. #is reduction in KLF2 may be mediated by 
the reduction of blood "ow to the CB during low output heart failure (myocardial infarction-CHF [MI-CHF]). 
Together, these results strongly suggest that potentiation of the CB-mediated chemore"ex function may be related 
to changes in cardiac output. However, there are no current studies showing the role of cardiac output on CB 
chemore"ex potentiation nor in cardiorespiratory changes once HF has been developed whereas other factors 
could play a role in disrupting normal CB function. #erefore, we aimed to determine whether alterations in 
cardiac output, in the setting of HF, induced CB chemore"ex potentiation and cardiac autonomic imbalance and 
if these alterations are associated with changes in KLF2 expression.
Echocardiography measurements show that the le' ventricular ejection fraction (LVEF) and le' ventricular frac-
tional shortening (LVFS) were signi$cantly reduced in MI-CHF rats vs. Sham (LVEF: 44.1 ± 3.7 vs. 77.2 ± 0.8%, 
n = 10 per group for MI-CHFvs. Sham, respectively) (LVFS: 23.4 ± 2.4 vs. 38.4 ± 0.6%, n = 10 per group for 
MI-CHF vs. Sham, respectively). In contrast, no di!erences in LVEF and LVFS between Sham vs. high output 
CHF (arterio-venous $stula CHF [AV-CHF]) rats were found (see Table 1). Le' ventricular end systolic volume 
(LVESV) and le' ventricular end diastolic volume (LVEDV) were signi$cantly increased in MI and AV-CHF 
rats compared to Sham animals showing clear signs of ventricular dilatation. Accordingly, cardiac hypertrophy 
Sham MI-CHF AV-CHF
BW (g) 501 ± 28 494 ± 37 545 ± 22
LVESD (mm) 4.3 ± 0.2 8.0 ± 0.3*,+ 4.8 ± 0.3
LVEDD (mm) 7.3 ± 0.2 9.8 ± 0.3* 8.8 ± 0.2*
LVESV (µl) 86.0 ± 7.5 346.0 ± 25.8* 111.1 ± 14.7*
LVEDV (µl) 278.9 ± 15.0 540.4 ± 30.8* 423.3 ± 24.6*
LVEF (%) 70.5 ± 2.0 35.9 ± 1.4*,+ 71.0 ± 1.1
LVFS (%) 41.3 ± 1.7 18.2 ± 0.8*,+ 41.9 ± 0.8
Table 1. Echocardiographic parameters in Sham, MI-CHF and AV-CHF. Values are means ± SEM. Body 
weight (BW), le' ventricular end-systolic diameter (LVESD), le' ventricular end-diastolic diameter (LVEDD), 
le' ventricular end-systolic volume (LVESV), le' ventricular end-diastolic volume (LVEDV), le' ventricular 
ejection fraction (LVEF) and le' ventricular fractional shortening (LVFS). *p < 0.05 vs. Sham; and +p < 0.05 vs. 
AV-CHF, Sidak post-hoc test a'er one-way ANOVA, n = 10 per group.
Figure 1. Rats with myocardial infarction (MI-CHF) and arteriovenous $stula (AV-CHF) have similar degrees 
of cardiac hypertrophy. (A) Representative images of hearts obtained in one Sham rat, one rat with MI-CHF and 
one rat with AV-CHF. Note the large ventricular dilation in both MI-CHF and AV-CHF vs. Sham condition. (B) 
Cardiac hypertrophy (heart weight/body weight [HW/BW]) was evident in both MI-CHF and AV-CHF rats 
compared to Sham rats. *p < 0.05 vs. Sham condition, Sidak post-hoc test a'er one-way ANOVA, n = 6 rats.
www.nature.com/scientificreports/
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was evident in the hearts harvested from both MI-CHF and AV-CHF rats (Fig. 1). Indeed, heart to body weight 
ratio was signi$cantly increased in MI-CHF and AV-CHF rats (4.7 ± 0.3 and 4.5 ± 0.4 vs. 3.2 ± 0.1 mg/g, n = 6 
per group for MI, AV and Sham rats, respectively). No statistical di!erences were found when comparing MI vs 
AV-CHF rats.
Carotid artery blood "ow in Sham, MI and AV-CHF rats was 
used as a surrogate for the estimation of blood perfusion to the CB region (Fig. 2). Carotid artery blood "ow 
was markedly reduced in MI-CHF rats compared to both Sham and AV-CHF Rats (18.1 ± 2.7 vs. 27.5 ± 4.7 and 
35.04 ± 1.8 ml/min, n = 10 per group for MI vs. Sham and AV-CHF rats, respectively). In addition, no di!erences 
in carotid artery blood "ow were found between Sham and AV-CHF group. Consistently with previous $ndings, 
CB-mediated chemore"ex drive was signi$cantly increased in MI-CHF rats compared to Sham rats6 (Fig. 3). 
Indeed, minute ventilation (VE) in normoxia (FIO2 21%) in MI-CHF rats was 87.0 ± 9.4 ml/min/100 g and in 
Sham rats was 39.9 ± 3.5 ml/min/100 g (n = 6 per group). Interestingly, AV-CHF rats displayed resting normoxic 
VE values comparable to the ones observed in Sham rats (32.3 ± 2.8 vs. 39.9 ± 3.5 ml/min/100 g, n = 10 per group 
for AV-CHF vs. Sham, respectively). Hypoxic ventilatory response (FIO2 10%) was markedly elevated in MI-CHF 
rats compared to Sham condition (222.1 ± 28.7 vs. 112.9 ± 12.2 ml/min/100 g of rat, n = 6 per group for MI-CHF 
vs. Sham, respectively). Interestingly, the ventilatory response to hypoxia in AV-CHF rats was signi$cantly lower 
compared to the ones obtained in Sham and MI-CHF rats (Fig. 3 n = 6 per group).
Figure 2. Carotid artery blood "ow in low output and high output heart failure. (A) Representative traces of 
carotid artery blood "ow, assessed by Doppler at rest in one Sham rat, one MI-CHF rat and one AV-CHF rat. 
(B) Summary data showing carotid artery blood "ow. Note that blood "ow to the CB region was signi$cantly 
reduced in MI-CHF vs. Sham. Also note that AV-CHF rats display similar blood "ow values compared to Sham 
rats. *p < 0.05 vs. Sham; +p < 0.05 vs. AV-CHF condition, Sidak post-hoc test a'er one-way ANOVA, n = 6 rats.
Figure 3. Carotid body-mediated chemore"ex function in heart failure rats. #e hypoxic ventilatory response 
was increased in MI-CHF rats compared to Sham condition. However, in AV-CHF the peripheral chemore"ex 
ventilatory response to acute hypoxic stimulation was blunted. ***p < 0.001 vs. Sham; *p < 0.05 vs. Sham; 
+p < 0.001 vs. AV-CHF; and +p < 0.05 vs. AV-CHF, Sidak post-hoc test a'er one-way ANOVA, n = 6 rats.
www.nature.com/scientificreports/
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Heart rate variability was decreased in both MI-CHF 
and AV-CHF rats compared to Sham (Fig. 4A). To fully determine which component of autonomic control to the 
heart was altered during HF condition, we studied cardiac chronotropic responses during acute sympatho-vagal 
blockage using propranolol and atropine, respectively. Compared to Sham rats, MI-CHF and AV-CHF rats dis-
played autonomic imbalance, characterized by an increased cardiac sympathetic out"ow and parasympathetic 
withdrawal (Fig. 4B and C). Indeed, we found that MI-CHF rats showed a 4.5-fold increase in the heart rate (HR) 
response to sympathetic blockage compared to Sham values (Fig. 4B; n = 4 per group, P < 0.001). Also, AV-CHF 
rats showed a 2.5-fold increase in the sympathetic control of HR compared to Sham rats (Fig. 4B; n = 4 per 
group P < 0.01). In addition, we found that MI-CHF rats displayed augmented sympatho-excitation compared 
to AV-CHF rats despite both were on HF (Fig. 4B). Furthermore, a similar degree of parasympathetic withdrawal 
was found in MI-CHF and AV-CHF rats compared to Sham (n = 4 per group, P < 0.001). Indeed, the HR change 
during parasympathetic blockade in MI-CHF rats was 31.6 ± 6.6 bpm compared to 33.5 ± 6.5 bpm obtained in 
AV-CHF rats and 96.2 ± 9.9 bpm obtained in Sham rats (n = 4 per group) (Fig. 4C). No di!erences in resting HR 
or BP were found between groups (Table 2).
Resting breathing disturbances were also observed in both MI-CHF and AV-CHF rats when compared to 
Sham rats. Respiratory disorders were mainly associated with a high prevalence of apneas and hypopneas while 
rats were resting in normoxia. #e incidence of apnea and hypopnea (AHI) were scored in all three groups of rats 
(Fig. 5). Compared to Sham rats, MI-CHF rats displayed 176 ± 31% more incidence of apneas/hypopneas while 
AV-CHF rats showed a 226 ± 38% increase in AHI compared to Sham (n = 6 per group).
KLF2 was constitutively expressed in the 
CB from Sham rats (Fig. 6). Consistent with previous $ndings11, 20, 21, MI-CHF rats showed a trend for a decreased 
expression of KLF2 in the CBs compared to Sham rats (p = 0.34; n = 4 per group). In contrast, AV-CHF rats dis-
played normal KLF2 expression, comparable to that observed in Sham rats (p = 0.68; n = 4 per group).
Figure 4. Myocardial infarction (MI-CHF) and arteriovenous $stula (AV-CHF) rats display autonomic 
imbalance. (A) #e total power of heart rate variability (HRV) was decreased in MI-CHF and AV-CHF vs. 
Sham condition. (B) MI-CHF and AV-CHF rats display cardiac parasympathetic withdrawal and enhanced 
sympathetic cardiac tone as evidenced by a decreased tachycardic response (∆HR) following i.p. bolus 
of atropine (1 mg/kg) and an increased bradycardic response (C) following propranolol (1 mg/kg, i.p.), 
respectively. ***p < 0.001, **p < 0.01 and *p < 0.05 vs. Sham condition, Sidak post-hoc test a'er one-away 
ANOVA, n = 4 rats.
www.nature.com/scientificreports/
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In the present study we show that CB chemore"ex potentiation is strongly associated with reduced cardiac out-
put in the setting of HF. #e main $ndings of the present study are: i) low output HF rats show a trend to display 
reduced KLF2 expression levels in the CB and an enhanced CB chemore"ex drive, ii) high output HF rats have 
normal KLF2 expression in the CB and reduced CB chemore"ex function, and iii) autonomic imbalance and 
breathing disturbances in high output HF are not related to CB chemoreceptor potentiation.
Previous studies indicate that CB chemore"ex function is enhanced during the development of low output HF5, 6. 
Furthermore, the presence of heightened CB chemore"ex drive has been associated with the activation of the 
sympathetic nervous system and with the development of altered resting breathing patterns6, 20, 22, 23. Indeed, HF 
patients with a reduced EF as well as animal models exhibit increased chemosensitivity5, 15, 19. Accordingly, we 
have previously shown in two low output HF models that irregular breathing patterns are critically dependent on 
the CB inputs since chronic denervation of the CB results in normalization of breathing13. In the present study, 
we con$rm and extend previous $ndings showing the relevance of the CB to altered breathing patterns on low 
output HF. We show for the $rst time that in experimental high output HF the CB chemore"ex function remains 
normal, comparable to that observed in control animals. Interestingly, AV-CHF rats displayed similar incidence 
of apneas and hypopneas compared to MI-CHF rats despite the marked di!erence in CB chemore"ex drive. It 
is worth noting that human HF patients with no reductions in EF also displayed signs of periodic breathing23. 
#erefore, we hypothesize that other factors may play a role in the development of disordered breathing in 
AV-rats. One potential mechanism that may contribute to cardiorespiratory alterations in AV-CHF rats may be 
related to the activation of brainstem central nervous system pathways associated with cardiovascular and breath-
ing regulation. Indeed, Shigematsu et al.38 showed that AV-CHF rats displayed neural activation at the nucleus of 
the solitary tract, a well know cite for the integration of respiratory and barore"ex activity. Future studies will be 
needed to understand the precise mechanisms that underlie ventilatory disturbances in high output HF.
Excessive sympathetic out"ow is a hallmark of HF, and contributes to cardiac arrhythmias, cardio-renal syn-
drome, and deterioration of cardiac function22–26. It is well established that acute and/or chronic activation of 
the CBs enhances sympathetic drive11, 14, 15, 22, 23, 27. Our previous studies indicate that heightened CB chemore-
"ex drive contributes to cardiac autonomic imbalance in HF12, 13. In the present study we showed that rats with 
MI induced HF exhibit enhanced CB chemore"ex drive and cardiac autonomic imbalance characterized by 
Sham MI-CHF AV-CHF
SBP (mmHg) 99.2 ± 4.5 96.9 ± 3.8 100.4 ± 5.6
DBP (mmHg) 75.3 ± 2.2 74.7 ± 2.1 69.9 ± 2.4
PP (mmHg) 23.9 ± 8.8 22.3 ± 2.2 30.5 ± 3.7
MAP (mmHg) 83.2 ± 2.5 82.1 ± 2.6 80.1 ± 3.4
HR (bpm) 385.8 ± 7.1 399.5 ± 12.1 361.4 ± 13.9
VT (ml 100 g−1) 0.37 ± 0.03 0.47 ± 0.02*,+ 0.35 ± 0.03
RF (breath 
min−1)
116.4 ± 7.4 168.3 ± 13.3*,+ 100.1 ± 8.0
Table 2. Resting hemodynamics and respiratory physiological parameters in Sham, MI-CHF and AV-CHF. 
Values are means ± SEM. Systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), 
mean arterial blood pressure (MAP), heart rate (HR), tidal respiratory volume (VT) and respiratory frequency 
(RF). *p < 0.05 vs. Sham; and +p < 0.05 vs. AV-CHF, Sidak post-hoc test a'er one-way ANOVA, n = 6 per 
group.
Figure 5. Incidence of apnea-hypopnea in rats with low output heart failure (MI-CHF) and high output heart 
failure (AV-CHF). #e apnea-hypopnea index (AHI) was increased in both MI and AV CHF rats vs. Sham 
condition. **p < 0.01 and *p < 0.05 vs. Sham condition, Sidak post-hoc test a'er one-way ANOVA, n = 6 rats.
www.nature.com/scientificreports/
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Figure 6. Krüppel-like factor 2 (KLF2) expression is reduced in myocardial infarction (MI-CHF) but normal 
in arteriovenous $stula (AV-CHF) rats. (A) Fluorescence intensity for KLF2 in the CB from MI-CHF was 
markedly decreased compared to Sham rats. Notably, AV-CHF rats showed similar KLF2 average "uorescence 
in the CB compared to Sham rats. (B) Representative immunoblots for KLF2 obtained in one Sham rat, one MI-
CHF rat and one AV-CHF rat and summary data showing the changes in the expression levels of KFL2 in MI-
CHF and in AV-CHF (p = 0.34, Sham vs. MI-CHF; p = 0.68, Sham vs. AV-CHF; Wilcoxon sum-rank test, n = 4). 
(C) Proposed model showing the role of blood "ow in CB sensitization in low vs high output heart failure. 
MI-CHF rats display reduced blood "ow to the CB that leads to a decreased expression of shear stress-sensitive 
transcription factors (i.e. KLF2) promoting CB glomus cells hyperactivity and $nally ending in an enhanced 
chemore"ex drive. On the contrary, AV-CHF rats display normal blood "ow to the CB with no changes in KLF2 
expression and normal CB-mediated chemore"ex drive. Dotted lines: extrapolation of the carotid circulation to 
the carotid bodies.
www.nature.com/scientificreports/
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sympathoexcitation and parasympathetic withdrawal. In addition, we show that rats with AV induced HF also 
displayed autonomic imbalance. However, in this model of HF, the autonomic change did not appear to be related 
to changes in the CB chemore"ex since no heightened CB chemore"ex drive was observed.
It has been shown that patients with HF with normal EF show an increased cardiac sympathetic drive28–30. It 
is well known that angiotensin II acting mainly through the activation of the angiotensin type 1 receptor, located 
in cardiovascular control neurons in the central nervous system induces sympathoexcitation31–34. Furthermore, 
it has been shown that angiotensin peptides mediate chronic increases in sympathetic out"ow in several car-
diovascular diseases including HF34–37. Shigematsu et al. showed that AV-rats have increased expression of the 
angiontensin converting enyme in the brainstem suggesting increased levels of angiotensin II in the central nerv-
ous system, particularly in areas related to cardiorespiratory control38. Also, angiotensin II-mediated increases 
in renal sympathetic nerve activity have been found to be increased by 3-fold in AV-CHF rats compared with 
control animals38. Together, these data suggest that increases in central and/or systemic levels of angiotensin II 
during the progression of AV-CHF may contribute to cardiac autonomic imbalance. Further studies should focus 
on the mechanism underlying neuronal activation in key central cardiovascular nuclei (i.e. paraventricular nuclei, 
rostral ventrolateral medulla, nucleus of the solitary tract).
It has been previously shown that reductions in blood "ow to the CB region in healthy animals are su+cient 
to cause peripheral chemore"ex sensitization11, 21. In these studies, chronic reductions in CB blood "ow in rabbits 
with otherwise normal cardiac function resulted in chemore"ex potentiation and alterations in angiotensin and 
nitric oxide metabolism that mimics that observed in HF rabbits with reduced EF. In the present study, we showed 
that in the setting of HF the potentiation of the CB-mediated chemore"ex drive is extremely dependent on the 
reductions in EF since only MI-CHF rats, a low output HF model, and not AV-CHF rats, a high output HF model, 
showed a signi$cant increase in CB chemore"ex sensitivity.
Furthermore, our data suggest that changes in cardiac output may trigger KLF2 expression changes in the CB. 
KLF2 is a master transcription factor involved in the vascular responses to shear stress at least in part by regulat-
ing the expression of angiotensin converting enzyme (ACE) and nitric oxide synthase (NOS)18, 21. Importantly, 
previous studies from our lab showed that an increase in angiotensin II and, a reduction in NO availability in the 
CB are both involved in chemore"ex potentiation in rabbits and rats with HF with reduced EF16, 19, 39. Accordingly, 
in the present study we found a reduced CB KLF2 expression in rats that displayed a marked reduction in carotid 
artery blood "ow (MI-CHF rats). Also, MI-CHF rats showed a signi$cant increase in CB-mediated chemore"ex 
drive. In contrast, AV-CHF rats with normal carotid artery blood "ow had normal KLF2 expression and no CB 
chemore"ex potentiation. Together, these results suggest that KLF2 expression changes within the CB are associ-
ated with the changes in ejection fraction in HF (Fig. 6).
Several limitations are inherent from our study. While CB chemore"ex potentiation appears to be related to 
decreases in ejection fraction in HF, we cannot rule out the possibility that altered cerebral blood "ow during 
low output HF also contribute to enhanced the re"ex response rising from the CB inputs. Indeed, It has been 
proposed that reductions in cerebral blood "ow could reset chemore"ex gain41–43. However, the compensatory 
adjustments following brain hypo-perfusion results in brain blood vessels dilation which in turn helps to wash 
out the build-up in CO2. #erefore, decreases in cerebral blood perfusion to chemosensitive related areas should 
result in decreases and not in increases in chemore"ex sensitivity. Unfortunately, there are no studies showing the 
contribution of cerebral blood "ow changes on chemore"ex sensitiviy in HF. Future studies are needed to evaluate 
the e!ects of decreased blood "ow to the brain on CB-mediated chemore"ex responses in the setting of HF.
In summary, low output HF rats present reduced CB KLF2 expression, enhanced chemore"ex drive, breathing 
instability and increased apnea incidence, and cardiac autonomic dysfunction compared to Sham rats. In contrast, 
high output HF rats showed normal CB KLF2 expression and CB chemore"ex function. Remarkably, high output 
HF rats showed comparable levels of breathing disturbances and cardiac autonomic imbalance compared to the 
ones observed in low output HF rats despite the presence of a reduced peripheral chemore"ex drive. Another 
factors may account for the elevated sympathetic activity and breathing irregularity in high output HF. Together, 
our results suggest that autonomic imbalance and ventilatory disorders in high output HF are not dependent on 
the enhancement of the peripheral chemore"ex drive. Future studies should focus on identifying the mechanisms 
that subside the development of autonomic and ventilatory impairment in high output HF.
#irty male Sprague-Dawley rats, weighing between 360 and 430 g, were used in these experiments. All experi-
ments were approved by the Bioethical Committee of the Universidad Autónoma de Chile and the Institutional 
Animal Care and Use Committee of the University of Nebraska Medical Center, and were carried out under the 
guidelines of the American Physiological Society, the Guía para el Cuidado y Uso de los Animales de Laboratorio 
from CONICYT and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Low output HF (MI-CHF) was produced by coronary 
artery ligation induced myocardial infarction (MI-rats) as previously described. Brie"y, rats were anesthetized 
(2% iso"urane/98%O2) and mechanically ventilated then a le' thoracotomy was performed. #e le' anterior 
descending coronary artery was ligated near its branch point from the aorta with a 6–0 silk suture. Following 
these maneuvers, the thorax was closed and the air within the thorax was evacuated. All animals were allowed 
to resume spontaneous respiration and recover from anesthesia. Rats were then housed in a temperature and 
humidity control environment with ad libitum access to food and water. All experiments were performed at 8 wk. 
a'er coronary artery ligation.
High-output HF (AV-CHF) was produced by volume 
overload induced by arterio-venous $stula (AV-rats) using the needle technique as described previously40. Brie"y, 
www.nature.com/scientificreports/
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rats were anesthetized (2% iso"urane/98%O2) and a midline abdominal incision was made to fully expose the 
aorta and vena cava. #en a longitudinal incision was made in the inferior vena cava and a $stula was created 
between the two vessels using 1.20 × 40 mm needle (BD PrecisionGlide). #e opening in the vena cava was then 
closed with tissue adhesive (Hystoacryl, Braun). #en, the abdomen was closed in layers. Rats were then housed 
in a temperature and humidity control environment with ad libitum access to food and water. All experiments 
were performed at 8 wk.
MI-Sham rats (n = 6) and AV-Sham rats (n = 4) were grouped into one single con-
trol groups. Sham operated rats were prepared in the same manner (described previously) but did not underwent 
MI and/or AV, respectively. All experiments were performed at 8 weeks post surgery.
Cardiac function and the degree 
of HF were determined by echocardiography (Vevo 770; Visualsonics, Inc.). Under iso"urane anesthesia, a 
two-dimensional, short-axis view of the le' ventricle (LV) was obtained at the level of the papillary muscles. 
M-mode tracings were recorded through the anterior and posterior LV walls, and anterior and posterior wall 
thicknesses (end-diastolic and end-systolic) and LV internal dimensions were also measured. Rats with ejection 
fraction (EF) of less than 45%, were considered to be in low output HF while rats showing preserved EF but with 
clear signs of chamber dilation (2.5 standard deviations from the mean obtained in control rats) where considered 
to be in high output HF. During the same session, rats underwent carotid artery Doppler to estimate blood "ow.
A'er 4 weeks of either 
MI or AV surgery, rats were implanted with a radio-telemetry device (Physiotel TA11PA-C40, Data Science 
International, USA) for measurement of blood pressure (BP) under 2% iso"urane anesthesia. Brie"y, the tip of a 
pressure-sensing catheter was inserted into the le' femoral artery and advanced to place the tip in the aorta. A'er 
14 days of recovery, continuous changes in BP and heart rate were measured in conscious freely moving animals 
at rest.
#e total power of heart rate variability (HRV) was calculated 
as an indirect measure of autonomic control to the heart as previously described11. Brie"y, BP recordings were 
obtained at 2 kHz over a 60 min period during the resting breathing test. Heart rate (HR) was derived from the 
inter-pulse interval. HRV was analyzed using the HRV extension for LabChart 7 so'ware (AD Instruments) over 
a 10-min recording characterized by the absence of movement-induced artifacts. Power spectral analysis was 
performed to calculate the total power of the HRV by integration of the whole spectrum. In addition, to estimate 
sympatho-vagal control of heart rhythm, the chronotropic HR responses during acute sympathetic blockage with 
propranolol (100 mg/kg i.p.) and parasympathetic blockade with atropine (100 mg/kg i.p.) was study.
Tidal volume 
(Vt), respiratory frequency (RF), and minute ventilation (VE: Vt x RF) were determined by unrestrained whole 
body plethysmography. Rats where placed in a Plexiglas chamber. #e chamber was sealed, except for an inlet and 
outlet port that allowed a continuous "ow of air through the chamber. Animals were kept for at least 1 hour before 
chemore"ex measurements were taken. #e plethysmograph was set-up in a dedicated room in the animal facility 
with controlled temperature and humidity. Tidal volume was measured by temporarily (15–30 s) sealing the air 
ports and measuring the pressure changes in the sealed chamber using a Validyne (MP-45) di!erential pressure 
transducer connected to an ampli$er and a PowerLab System (AD Instruments). Calibration was performed by 
injecting known volumes of air to the chamber once the experiment was $nished. Calibration was performed 
each day experiments were conducted. Resting breathing was recorded for 2 h while the rats breathed room air. 
Apnea episodes (cessation of breathing ≥ 3 breaths) and hypopneas (reductions ≥ 50% in Vt) were average dur-
ing resting breathing recordings. #e CB-mediated chemore"ex function was estimated by allowing the rats to 
breathe hypoxic (10% O2/balance N2) gas for 2–5 min under isocapnic conditions as previously described
6. All 
recordings were made at an ambient temperature of 25 ± 2 °C. During chemore"ex testing, respiratory variables 
(RF and Vt) were averaged for at least 20 consecutive breaths over a period of 4 min of inspired hypoxic challenges.
KLF-2 protein expression within the CB was assessed using immu-
nostaining as previously described20. Brie"y, rats were anesthetized and perfused intracardially with bu!ered 
paraformaldehyde (PFA 4%, Sigma) for 10 min. #e carotid artery bifurcations including the CBs were harvested 
from the rats and post$xed by in the same $xative solution for 12 h at 4 °C. Tissue was then cryopreserved using 
a sucrose gradient (5%, 10%, 20% in PBS), and embedded in OCT. Sections containing the CB (10 µm) were 
blocked/permeabilized in 0.5% Triton X-100, 2% $sh skin gelatin (Sigma-Aldrich), 1%BSA in PBS for 1 hour 
at RT. Sections were incubated overnight at RT with a mixture of an goat anti-KLF2 polyclonal antibody (1:100 
in the same blocking media, Abcam) and an mouse anti-TH monoclonal antibody (1:250 in the same blocking 
media, Millipore) the latter used as a positive control for CB chemoreceptor (glomus) cell recognition. A'er being 
washed with PBS, tissue sections were incubated for 1 h with a mixture of Alexa-Fluor 488 rabbit anti goat IgG 
(1:200, Molecular Probes) and Alexa-Fluor 546 rabbit anti-mouse IgG (1:200, Molecular Probes). Finally, sections 
were mounted (Vectashield, Vector Laboratory) and visualized using a confocal laser microscope (Leica).
KLF2 protein expression was studied as previously described20. Brie"y, a'er euthanizing the rats, the carotid 
sinus region containing the CBs, was quickly removed and snap frozen on dry ice and stored at −80 °C. Tissue 
was lysed in 200 µL of RIPA bu!er with fresh protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and total 
protein concentration was assessed using a #ermo Scienti$c BCA Assay kit (Waltham, MA) prior to Western 
blot analysis. Samples were loaded onto a 7.5% SDS-PAGE gel (50 µg/20 µl per well) and electrophoresis was 
performed. Fractionated proteins were then transferred to a PVDF membrane (Millipore, Billerica, MA) and the 
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membrane probed with the following antibodies overnight: rabbit anti- KLF2 (1:750, Novus Biological), and/or 
mouse anti- β-actin (1:500–1:1,000, Santa Cruz). Following washes with PBST, the appropriate secondary anti-
bodies (Li-Cor Biosciences, Lincoln, NE) were added to each membrane. Blots were developed using a Li-Cor 
Odyssey scanner and quantitative analysis of band densitometry was performed using the Li-Cor Odyssey so'-
ware. #e relative amount of protein of interest was calculated as the ratio of intensity of the band relative to the 
intensity of the housekeeping.
Data were expressed as means ± S.E.M. All data were subjected to Shapiro-Wilk nor-
mality test. #e di!erences on hypoxic ventilatory response was analyzed by two-ways ANOVA (2 x 3), following 
Sidak post-hoc. To determine the di!erences between groups on echocardiography parameters, resting hemo-
dynamics and respiratory physiological parameters, cardiac hypertrophy, carotid artery blood "ow, autonomic 
control and AHI, One-way ANOVA followed by Sidak post-hoc was used. For KLF-2 expression (nonparametric 
data), the Wilcoxon sum-rank test was employed. A p value of <0.05 was considered statistically signi$cant.
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